[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/02, MON) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 넥스아이, 불응성암 新타깃 차별성 “내후년 흑자전환”
[https://www.biospectator.com/news/view/30245](https://www.biospectator.com/news/view/30245)

 큐로셀, ‘CAR-T’ 2차치료 적응증 확대 "3상 IND 신청"
[https://www.biospectator.com/news/view/30254](https://www.biospectator.com/news/view/30254)

 아이엠바이오, GC녹십자와 '자가면역 항체' MTA 계약
[https://www.biospectator.com/news/view/30259](https://www.biospectator.com/news/view/30259)

 [인사]삼양그룹, 정기 임원인사
[https://www.biospectator.com/news/view/30261](https://www.biospectator.com/news/view/30261)

 드렌바이오, 3.5억弗 유치.."CD94 항체 허가임상 개발" 
[https://www.biospectator.com/news/view/30242](https://www.biospectator.com/news/view/30242)

 핀테라퓨틱스, '신규 E3 리가아제' 분자접착제 "발표" 
[https://www.biospectator.com/news/view/30257](https://www.biospectator.com/news/view/30257)

 GC녹십자, 3Q 매출 5221억·영업이익 492억 
[https://www.biospectator.com/news/view/30264](https://www.biospectator.com/news/view/30264)

 제일약품, 중앙연구소장에 박준석 전무 선임
[https://www.biospectator.com/news/view/30266](https://www.biospectator.com/news/view/30266)

 '재즈 분사' 세타라, 시리즈A 9000만弗.."TRPV4 저해제" 
[https://www.biospectator.com/news/view/30253](https://www.biospectator.com/news/view/30253)

 동아ST, 뇌전증 치료제 ‘엑스코프리’ 국내 출시 
[https://www.biospectator.com/news/view/30265](https://www.biospectator.com/news/view/30265)

 큐리언트, 'CDK7 저해제' 소아뇌종양 美임상 "IND 승인"
[https://www.biospectator.com/news/view/30268](https://www.biospectator.com/news/view/30268)

 리가켐, 'HER2 ADC' post-엔허투 유방암서 "ORR 50%"
[https://www.biospectator.com/news/view/30263](https://www.biospectator.com/news/view/30263)

 올릭스, '황반변성 RNAi' 미국 2a상 "IND 제출"
[https://www.biospectator.com/news/view/30267](https://www.biospectator.com/news/view/30267)

 씨어스, 제로웹과 AI 재택 환자 모니터링 협력 MOU 
[https://www.biospectator.com/news/view/30270](https://www.biospectator.com/news/view/30270)

 핀테라, 'CK1α 분해약물' ACC "美패스트트랙 지정"
[https://www.biospectator.com/news/view/30269](https://www.biospectator.com/news/view/30269)

 지아이이노, 트리오어와 '마스킹 다중항체' 개발 MOU 
[https://www.biospectator.com/news/view/30274](https://www.biospectator.com/news/view/30274)

 인사이트, 'KRAS G12D' 병용 췌장암 1상 "ORR 81%"
[https://www.biospectator.com/news/view/30222](https://www.biospectator.com/news/view/30222)

 GC녹십자, 콜롬비아 백스테라와 '독감백신' 원액공급 계약
[https://www.biospectator.com/news/view/30271](https://www.biospectator.com/news/view/30271)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/02, MON) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)